titlesubmit dateissue date
Now showing items 1-19 of 19
c-Jun N-terminal kinase phosphorylation is a biomarker of plitidepsin activity
Cancer stem cells from human glioblastoma resemble but do not mimic original tumors after <i>in vitro</i> passaging in serum-free media
Controlled release microspheres loaded with BMP7 suppress primary tumors from human glioblastoma
Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies
E-cadherin downregulation sensitizes PTEN-mutant tumors to PI3Kβ silencing.
EGFR feedback-inhibition by Ran-binding protein 6 is disrupted in cancer
Identification and characterization of Cardiac Glycosides as senolytic compounds
In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells.
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth
MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma
Mesenchymal stem cell carriers enhance antitumor efficacy of oncolytic adenoviruses in an immunocompetent mouse model
NSD2 contributes to oncogenic RAS-driven transcription in lung cancer cells through long-range epigenetic activation
Pharmacological inhibition of p38 MAPK reduces tumor growth in patient-derived xenografts from colon tumors.
Preclinical Test of Dacomitinib, an Irreversible EGFR Inhibitor, Confirms Its Effectiveness for Glioblastoma.
Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia.
Targeting Glioma Initiating Cells with A combined therapy of cannabinoids and temozolomide
Targeting OGG1 arrests cancer cell proliferation by inducing replication stress.
The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status
Tissue-derived mesenchymal stromal cells used as vehicles for anti-tumor therapy exert different in vivo effects on migration capacity and tumor growth